Summary
A total of 13 patients with drug-induced psychosis in Parkinson's disease were treated with two non-classical neuroleptics-clozapine and fluperlapine. Patients mainly complained about severe hallucinatory symptoms and different degrees of paranoid delusions. Complete relief was observed in 8 patients, moderate improvement in 3 and no effects in 2. Parkinsonian disability did not increase under neuroleptic medication with clozapine and fluperlapine, but could be ameliorated by additional L-dopa or bromocriptine medication. The non-classical neuroleptics employed are dopamine D2 blocking agents with a preferential binding to mesolimbic, mesocortical and hippocampal D2 receptors and no substantial binding to striatal dopamine receptors. Restricted use of these two neuroleptics is necessitated because of the danger of agranulocytosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackenheil M, Hippius H (1977) Clozapine. In: Usdin E, Forrest I (ed) Psychotherapeutic drugs, vol 2, part 2. Marcel Dekker Inc, New York Basel, pp 923–956
Andén NE, Stuck G (1973) Effect of clozapine on the turn-over of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346–348
Andermann B, Griffith RW (1977) Clozapine-induced agranulocytosis: A situation report up to August 1976. Eur J Clin Pharmacol 11:199–201
Beasley BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with Tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37:155–156
Birkmayer W (1966) Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien Z Nervenheilkunde 23:128–139
Birkmayer W, Neumayer E (1972) Die Behandlung der Dopa-Psychosen mit L-Tryptophan. Nervenarzt 43:76–78
Birkmayer W, Riederer P, Rausch WD (1979) Neuropharmacological principles and problems of combined L-Dopa treatment in Parkinson's disease. Adv Neurol 24:499–510
Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit. Biochemie, Klinik, Therapie. Springer, Wien, New York
Bischoff S, Delini-Stula A, Maitre L (1985) Blockade der Dopamin-Rezeptoren im Hippokampus als Indikator antipsychotischer Wirksamkeit: Korrelationen zwischen neurochemischen und psychopharmakologischen Wirkungen von Neuroleptika. In: Pflug B, Foerster K, Straube E (Hrsg) Perspektiven der Schizophrenie-Forschung. Gustav Fischer, Stuttgart New York, S 87–103
Caine DB (1983) Ergot derivates and extrapyramidal disease. In: Caine DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 357–361
Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:164–173
Eichenberger E (1984) Pharmacology of Fluperlapine compared with Clozapine. Arzneim Forsch/Drug Res 34:110–113
Gehlen W, Müller J (1974) Zur Therapie der Dopa-Psychosen mit L-Tryptophan. Dtsch Med Wochenschr 99:457–463
Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and Haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424
Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139:494–497
Halgren E (1982) Mental phenomena induced by stimulation in the limbic system. Human Neurobiol 1:251–260
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442
Idänpään-Heikkilä J, Alhava E, Olkinnora M, Palva IP (1977) Agranulocytosis during treatment with Clozapine. Eur J Clin Pharmacol 11:193–198
Korsgaard S, Noring U, Gerlach J (1984) Fluperlapine in tardive dyskinesia and parkinsonism. Psychopharmacology 84:76–79
Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29:1253–1260
Lieberman A, Kupersmith M, Neophytides A (1980) Bromocriptine in Parkinson's disease: report on 106 patients treated up to 5 years. In: Caine DB, Goldstein M, Lieberman A, Thorner M (eds) Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Raven Press, New York, pp 245–253
Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D (1981) Treatment of advanced Parkinson's disease with pergolide. Neurology 31:675–682
Marsden CD, Fahn S (1981) Problems in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 1–7
Moskovitz C, More H, Klawans H (1978) Levodopa induced psychosis: a kindling phenomenon. Am J Psychiatry 135:218–226
Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogene Psychosen beim Parkinsonsyndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiatr 52:207–214
Stern Y, Mayeux R, Ilson J, Fahn S, Cote L (1984) Pergolide therapy for Parkinson's disease: Neurobehavioural changes. Neurology 34:201–204
Sweet RD, McDowell FH, Feigenson JS, Loranger AW, Goodell H (1976) Mental symptoms in Parkinson's disease during chronic treatment with leveodopa. Neurology 26:305–310
Wieser HG (1983) Electroclinical features of the psychomotor seizure. Gustav Fischer, Butterworth, Stuttgart New York
Woggon B, Heinrich K, Küfferle B, Müller-Oerlinghausen B, Pöldinger W, Rüther E, Schied HW (1984) Results of a multicenter AMDP study with Fluperlapine in schizophrenic patients. Arzneim Forsch/Drug Res 34:122–124
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scholz, E., Dichgans, J. Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235, 60–64 (1985). https://doi.org/10.1007/BF00380972
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00380972